Cannabinoid receptor antagonists and the metabolic syndrome: Novel promising therapeutical approaches.
Recent findings in animals and in humans have shown that cannabinoid type 1 receptor antagonists are suitable to become the most promising validated class of drugs to tackle obesity and related disorders. This mini-review will provide a concise and updated revision of the state of art on this topic.
Cervino
C
C
Endocrinology Unit, Dept. of Internal Medicine and Gastroenterology, CRBA, S. Orsola-Malpighi Hospital, Via Massarenti, 9, 40138 Bologna, Italy.
Pasquali
R
R
Pagotto
U
U
D063386:Cannabinoid Receptor Agonists; D063387:Cannabinoid Receptor Antagonists; D006801:Humans; D024821:Metabolic Syndrome / Q000188:drug therapy*; D009765:Obesity / Q000188:drug therapy; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D000077285:Rimonabant
D063386:Cannabinoid Receptor Agonists; D063387:Cannabinoid Receptor Antagonists; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant